Teva to host conference call to discuss data from the completed phase 3 solaris trial for olanzapine lai (tev-‘749) on september 22, 2025 after presentations at the psych congress annual meeting

Tel aviv, israel, sept. 16, 2025 (globe newswire) -- teva pharmaceutical industries ltd. (nyse and tase: teva) today announced plans to present data from the completed phase 3 solaris trial at the 2025 psych congress annual meeting, taking place from september 17 – 21, 2025, in san diego, california.
TEVA Ratings Summary
TEVA Quant Ranking